Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and leading to ...

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single ...

T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. A study demonstrates that a different immunotherapy approach ...

The lab of one University of Illinois researcher is receiving a hefty grant, which will be used towards cancer research. On ...

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...

Antibody-drug conjugates (ADCs) combine antibodies with cytotoxic drugs to target cancer cells while minimizing damage to ...

The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.

The first patient blood samples, just weeks away, will open a new chapter in medicine’s ongoing search for a therapy that ...

Bacteria-based therapies represent an exciting breakthrough in cancer treatment, harnessing their remarkable ability to ...